Byetta Is “Approvable” As Stand-Alone Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly/Amylin'sByetta type 2 diabetes agent is "approvable" at FDA as a stand-alone therapy in conjunction with the April 29 approval of exenatide as an adjunct to other oral treatments, the firms said
You may also be interested in...
Amylin/Lilly Eye Byetta sNDA As Monotherapy In 1H 2008
Lilly tells DAILY that as monotherapy for type 2 diabetes, exenatide could be prescribed to patients earlier in treatment.
Amylin/Lilly Eye Byetta sNDA As Monotherapy In 1H 2008
Lilly tells DAILY that as monotherapy for type 2 diabetes, exenatide could be prescribed to patients earlier in treatment.
Amylin Halts Development Of Symlin With Approved Appetite Suppressants
The 2009 filing timeline for once-weekly exenatide could be hastened if FDA does not require bioequivalence data, firm says.